September 27, 2018 Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors
September 14, 2018 Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
August 28, 2018 Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality
June 5, 2018 UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
May 23, 2018 Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing
May 21, 2018 UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
May 16, 2018 Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breakter at the International Investigative Dermatology Congress
May 15, 2018 Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
April 3, 2018 Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
March 12, 2018 Sienna Biopharmaceuticals announces First Patient Dosed in Proof-Of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
February 22, 2018 Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
February 22, 2018 New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
February 14, 2018 UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
February 14, 2018 Sienna Biopharmaceuticals announces First Patient Dosed in First-In-Human Trial of Topical SNA-125
February 5, 2018 Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
January 23, 2018 UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option
